Does oral single-ingredient vitamin B6 improve depressive symptoms in adults?

Useful facts when choosing a product

• Pyridoxine/HCl is not clinically equated with pyridoxal, pyridoxamine or PLP/P5P.
• Research doses are not individual doses and differ from total diet-plus-supplement exposure.
• B6+B12+folate, magnesium+B6 and multivitamins are not treated as isolated B6 effects.

What the research actually shows

# Does oral single-ingredient vitamin B6 improve depressive symptoms in adults?

TASK-1026 / R01-066 · Complete research report · 2026-09-17

Verification record time: 2026-09-17T05:09:10+09:00

## Reader answer

Oral single-ingredient vitamin B6 has signals of improvement in depressive symptoms, but efficacy as standalone treatment for general adults or diagnosed major depressive disorder (MDD) is not established. The closest 2026 study is an exploratory DASS-42 symptom-subgroup analysis, with its key adjusted test comparing 19 B6 participants against 39 pooled placebo-plus-B12 participants. The adjusted point contrast/CI, clinical importance, nutritional status and antidepressant co-use are insufficiently established; this is not zero effect, equivalence, absence of human research, or individual dosing advice. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852) [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Efficacy C / 50 points; safety Caution; manuscript quality A**. This is a current assessment under supplied rules, not a success probability, official GRADE or external-review score. Quality A is the author's completeness assessment, not journal certification or an error-free guarantee.

## Question versus verified study facts

The fixed question concerns oral single-ingredient vitamin B6 for depressive symptoms in adults. PHQ-9 was a candidate measurement in the task, not a verified measured outcome in this extraction. Actual evidence uses DASS-42 depression, adult long MFQ, BDI-II, HADS depression, HAM-D and separate postpartum-prevention EPDS. Diagnosed MDD is not interchangeable with scale-defined symptoms. General recruitment, OC users, fibromyalgia, schizophrenia with minor depression and at-risk pregnancy remain separate populations.

A single supplement ingredient does not mean treatment without antidepressants or psychotherapy. The key Field study did not ask about antidepressants; most fibromyalgia participants used them. Pyridoxine/HCl, pyridoxal, pyridoxamine and PLP/P5P are verified separately, and nominal milligrams are not converted into unverified active equivalents. Unknown deficiency/sufficiency is not classified as nondeficiency. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

All fields of the 3,141-record index were searched and originals 127/486/580/1059/3095/3096/3097/3098/3141 compared. No exact completed independent claim matched; operation=new. Record 1059 concerns B-vitamin combination depression prevention. Existing B6 source, extraction, search and safety maps were reused, without changing the MCI3141 manuscript or grade. The later supplied deployment receipt/completion ledger establishes its published status rather than the historical unassigned original manifest. This is review of supplied records, not a new server inspection or deployment. See duplicate_audit.json and provenance.json.

## Evidence overview

| Study | Population/denominator | Actual comparison and depression endpoint | Role | |---|---|---|---| | Field et al. 2026 [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) | Symptomatic n=58: B6 19, placebo 18, B12 21; adjusted pooled control 39 | DASS-42 depression subscale at 30-40 days, 0-42, higher worse | Closest symptom-defined single-B6 evidence, but an exploratory subgroup in one program, not a confirmatory MDD-treatment trial. | | Field et al. 2022 [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852) | MFQ final B6 47/B12 48/placebo 51; B6-placebo n=98 | Scheduled 30-35-day follow-up; 33-item adult long MFQ | Retained as a nonsignificant depression result in the same program, not an independent replication of the 2026 report. | | Curtin and Johnston 2022/2023 [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/) | Eight healthy college OC users; total allocation/attrition details inaccessible | BDI-II after each four-week period, four-week washout; POMS separate | Positive but very small and OC-specific crossover study, not same-population clinical replication for general depression or MDD. | | Ghavidel-Parsa et al. 2022 [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7) | 90 randomized 45/45; 31 B6 and 29 placebo completers | HADS depression at 60 days (table says eight weeks), 0-21, higher worse | Indirect counterevidence for B6 added to fibromyalgia care, not pooled with drug-free treatment of general depression. | | Shiloh et al. 2001 [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/) | Nine patients with schizophrenia and minor depression | HAM-D over four weeks; version/range unverified | Uncontrolled augmentation of stable neuroleptic treatment, with route and generalizability limits. | | Khodadad et al. 2021 [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/) | 86 allocated 43/43; 40/41 completed | 80 mg/day from week 28 to birth, then 40 mg/day for one month; EPDS at six weeks postpartum | Separate pregnancy/postpartum-prevention question, not pooled with general depression treatment or effects in nutrient-sufficient adults. |

## Study-specific full extraction

The states below describe the verified access boundary. Mixed fields distinguish confirmed values from component-specific gaps and reasons; nonreporting and inaccessibility are not treated as synonyms.

### Field et al. 2026 — S01

Closest symptom-defined single-B6 evidence, but an exploratory subgroup in one program, not a confirmatory MDD-treatment trial. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

Source access: `full_text_html_and_pdf_screenshots`; Methods 2.1-2.3; Tables 1-3; Results 3.1 and Figure 1; Discussion and funding; PDF pages 2-8.

**Population, diagnosis and severity — Confirmed; component-specific gaps stated separately.** General-population recruitment, ages 18-61, mean 23.3 (SD 7.9), predominantly women. The 58-person subgroup had DASS-D>=10, indicating at least mild questionnaire symptoms, not an interview-based MDD diagnosis. Overall age limits are not relabeled subgroup-specific limits. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Baseline scale, direction and range — Confirmed; component-specific gaps stated separately.** DASS-42 depression uses 14 items scored 0-3, total 0-42, higher worse. Symptomatic-group means (SD): placebo 13.9 (3.6) to 10.6 (7.7), B6 17.8 (6.7) to 8.2 (6.4), B12 15.7 (6.0) to 13.9 (8.6). These are baseline/end scores, not change-score SDs. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**PLP, deficiency and total intake — Not reported/not established; reason stated.** Blood PLP/B6 was not measured and baseline diet/total B6 exposure was not adequately characterized. Neither deficiency treatment nor verified nutrient sufficiency is established. Agreement to stop other B supplements was a study procedure, not individual advice. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Form, salt, active basis, route, dose and duration — Confirmed; component-specific gaps stated separately.** Single B6 100 mg/day as an oral pyridoxine hydrochloride tablet for 30-40 days. The report does not independently assay or resolve label B6 mass versus salt/free-base equivalents; no converted active dose is invented. The number 88 denotes B6 participants, not an 88-100 mg dose range. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Actual comparator, common care and co-treatment — Confirmed; component-specific gaps stated separately.** Separate arms used lactose placebo and B12 1000 micrograms/day as methylcobalamin, not B6+B12 combination treatment. The key ANCOVA compares B6 n=19 with pooled placebo n=18 plus B12 n=21, total 39. Antidepressant use was explicitly neither excluded nor asked about. Drug-free monotherapy, psychotherapy and medication stability cannot be established. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Denominators, completion and attrition — Internal source conflict retained.** Methods: 325 recruited, 268 with both DASS assessments, arms 86/88/94; abstract: 267. After 13 outlier exclusions, text says 254, although 268-13=255. Table 1 gives 83/81/90=254 and symptomatic arms 18/19/21=58. Relevant subgroup analyses use those 58, with the one-person discrepancy left unresolved. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Reported values, changes and between-group/adjusted analyses — Confirmed; component-specific gaps stated separately.** Improvement is baseline minus endpoint. B6 versus pooled controls: unadjusted F(1,56)=17.02, p<.001, partial eta squared=.23; baseline-adjusted F(1,55)=14.00, p<.001, partial eta squared=.20. Adjusted point difference and its CI are unreported. Table means yield reductions of 9.6, 3.3 and 1.8 points and a raw B6-placebo difference in reduction of 6.3 points, not an adjusted contrast. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Design, registered-primary status and multiplicity — Confirmed; component-specific gaps stated separately.** Computer randomization and double blinding are described, but analyses require completed measurements and remove MAD(k=3) outliers defined using baseline or post-treatment DASS totals. Higher baseline B6 scores, regression to the mean, exploratory analyses and unadjusted multiplicity limit inference. Registered-primary and prespecified-subgroup status were not verified; 2018-128-DF is ethics approval. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Clinical importance, response and remission — Not reported/not established; reason stated.** No validated MCID matched to this population, interval and between-group contrast, or response/remission definition and rate, was verified. A group mean below 10 is not a remission rate. Partial eta squared .20 is not a 20% symptom reduction; only statistical magnitude classification is supported. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Funding, product supply and conflicts — Confirmed; component-specific gaps stated separately.** University of Reading academic-employment support and donated Innopure tablets are acknowledged; authors declare no competing interests. This is not treated as wholly industry-free I2 evidence. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Study safety — Confirmed; component-specific gaps stated separately.** One B6 participant withdrew because of vivid dreams. No tingling or related recognized sensory symptoms were reported, but a complete randomized-arm adverse-event denominator and long-term surveillance are unavailable. Nonreporting is not proof of safety or zero risk. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

**Other endpoints not substituted — Not applicable.** DASS anxiety/stress and GABA, visual or cognitive mechanisms are not depression effect sizes. The additional high-normal (6-9) analysis has 42 participants in text versus 52 in the abstract and is not confirmatory. Other model-df and Figure 3 denominator discrepancies are separated from the core depression result. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512)

### Field et al. 2022 — S02

Retained as a nonsignificant depression result in the same program, not an independent replication of the 2026 report. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

Source access: `full_text_html_and_pdf_screenshots`; Methods 2.1, 2.3.2, 2.3.7; Tables 1-3; Results 3.2 and Figure 2; Discussion and acknowledgements; PDF pages 3-9.

**Population, diagnosis and severity — Confirmed; component-specific gaps stated separately.** General adult recruitment, 478 across the program, ages 18-58; not clinical MDD or severity-selected treatment recruitment. The MFQ analysis denominator is not 478. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Baseline scale, direction and range — Confirmed; component-specific gaps stated separately.** Adult self-report long MFQ has 33 items, higher scores indicating more depressive symptoms. Exact baseline/endpoint means are graphical and were not digitized or invented. The paper-specific numerical range and item-scoring implementation were not explicitly verified. This is not PHQ-9. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**PLP, deficiency and total intake — Not reported/not established; reason stated.** Blood B6/PLP and diagnosed deficiency are unverified. Dietary information was collected in some phases, but total intake and baseline sufficiency for the depression analysis group were not established. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Form, salt, active basis, route, dose and duration — Confirmed; component-specific gaps stated separately.** Oral B6 100 mg/day tablets; the source typo "pyroxidine hydrochloride" is retained as a note within the pyridoxine hydrochloride context. Scheduled follow-up was 30-35 days, with 40 tablets supplied for flexibility. No active-equivalent conversion was performed. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Actual comparator, common care and co-treatment — Confirmed; component-specific gaps stated separately.** Lactose placebo and a separate methylcobalamin B12 1000-microgram arm. B6-placebo and B12-placebo MFQ comparisons are separate. Depression-group antidepressant, psychotherapy and medication-change data are unreported; absence of treatment is not assumed. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Denominators, completion and attrition — Confirmed; component-specific gaps stated separately.** MFQ baseline counts were 52/52/54 (B6/B12/placebo), endpoint 52/51/53, final 47/48/51. The B6-placebo interaction uses 98 participants. Scores above 37 at baseline or endpoint were excluded. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Reported values, changes and between-group/adjusted analyses — Confirmed; component-specific gaps stated separately.** Group-by-time F(1,96)=3.08, p=.083, partial eta squared=.031 did not establish between-group depression improvement. Within-B6 t(46)=1.13, p=.263, d=.17 is a different statistic. Response/remission, between-group point difference/CI and MCID were not verified. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Design, registered-primary status and multiplicity — Confirmed; component-specific gaps stated separately.** Forty-two inferential tests were conducted without multiplicity correction. Tablet appearance differed, limiting masking; outlier and complete-data selection were noted. Registered-primary and prespecified depression-analysis status were not verified. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Clinical importance, response and remission — Not reported/not established; reason stated.** Response/remission definitions or rates, a validated between-group MCID and contrast CI were not verified for this analysis. A nonsignificant interaction is not an equivalence test. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Funding, product supply and conflicts — Confirmed; component-specific gaps stated separately.** Innopure donated supplements and authors declared no conflicts. A separate detailed financial grant statement was not verified in this paper; the 2026 funding wording is not copied as independent support. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Study safety — Not reported/not established; reason stated.** No complete MFQ-subgroup adverse-event or sensory-symptom table was verified. The later 2026 report of one withdrawal belongs to the same program and is not added as a separate study or event. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

### Curtin and Johnston 2022/2023 — S03

Positive but very small and OC-specific crossover study, not same-population clinical replication for general depression or MDD. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

Source access: `original_abstract_in_authors_institutional_record`; Abstract; publication and DOI metadata.

**Population, diagnosis and severity — Confirmed; component-specific gaps stated separately.** Eight healthy college women aged 18-25 using estrogen/progestin oral contraceptives for at least one year. An MDD diagnosis or depression-threshold enrollment was not specified in the accessed abstract. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Baseline scale, direction and range — Full text or detailed data inaccessible.** BDI-II use is confirmed. Exact baseline severity, item implementation/range and raw endpoint scores are unavailable without the full paper. POMS is a separate mood measure. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**PLP, deficiency and total intake — Confirmed; component-specific gaps stated separately.** The abstract reports dietary B6 of 1.2-1.4 mg/day, blood B6 measurement and no other supplement use. Exact PLP concentrations and deficiency criteria were not verified in the original abstract and were not filled from secondary conference summaries. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Form, salt, active basis, route, dose and duration — Confirmed; component-specific gaps stated separately.** Randomized double-blind crossover of oral B6 100 mg/day for four weeks and placebo for four weeks, separated by a four-week washout. Exact salt and active-dose basis are inaccessible. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Actual comparator, common care and co-treatment — Full text or detailed data inaccessible.** Placebo ingredients, sequence-specific analysis, carryover testing, total randomized/attrition counts and antidepressant/psychotherapy use are unavailable without full text. Maintaining normal diet and exercise was a common study procedure. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Denominators, completion and attrition — Full text or detailed data inaccessible.** The abstract describes eight women in the crossover analysis. Initial recruitment/randomization, period-specific losses and sequence-specific denominators are inaccessible without full text. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Reported values, changes and between-group/adjusted analyses — Confirmed; component-specific gaps stated separately.** BDI-II reportedly decreased by a relative 20% during B6 and increased by 11% during placebo, p=.046. These are not -20 points or a 31-point treatment difference. Paired raw-score contrast/CI, MCID and response/remission were not verified. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Design, registered-primary status and multiplicity — Full text or detailed data inaccessible.** Randomization and double blinding are stated in the abstract, but allocation concealment, registered-primary status, multiplicity and crossover carryover handling were not verified without full text. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Clinical importance, response and remission — Full text or detailed data inaccessible.** Relative BDI-II changes are reported; raw-score treatment contrast/CI, clinical importance and response/remission remain inaccessible. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Funding, product supply and conflicts — Full text or detailed data inaccessible.** The accessed author-institution abstract does not provide detailed funding or product-supply information; institutional affiliation and other studies are not substitutes. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

**Study safety — Full text or detailed data inaccessible.** Period-specific adverse events, withdrawals and sensory symptoms are inaccessible. Four-week exposure is not evidence of long-term neurological safety. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

### Ghavidel-Parsa et al. 2022 — S04

Indirect counterevidence for B6 added to fibromyalgia care, not pooled with drug-free treatment of general depression. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

Source access: `full_text_html_and_pdf_screenshots`; Methods and statistical analysis; Figure 1; Table 1 and Table 2; Funding and competing interests; PDF pages 5-7.

**Population, diagnosis and severity — Confirmed; component-specific gaps stated separately.** Ninety women with rheumatologist-confirmed 2016 ACR fibromyalgia, 45 per arm; no MDD or depression-score enrollment criterion. Completers were 31/29, mean ages 44.3/43.9; losses were 14/16, 30/90=33.33% overall. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Baseline scale, direction and range — Confirmed; component-specific gaps stated separately.** HADS depression uses seven 0-3 items, total 0-21, higher worse. B6: 7.93 (SD 3.87) to 7.25 (3.38); placebo: 6.53 (3.17) to 7.07 (3.98). HADS anxiety/total and SF-12 are separate endpoints. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**PLP, deficiency and total intake — Not reported/not established; reason stated.** PLP, confirmed B6 deficiency and total dietary intake were not established. CBC and inflammatory tests are not PLP measurements. Withdrawal/exclusion of other B6 products was part of the study procedure. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Form, salt, active basis, route, dose and duration — Confirmed; component-specific gaps stated separately.** Oral B6 40-mg tablets twice daily, 80 mg/day for 60 days, with visit at day 60 +/-3. Tables also say eight weeks; 60 days is not silently converted to exactly 56 days. The exact chemical salt/active-dose basis of the Iran Hormone product was not explicitly verified. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Actual comparator, common care and co-treatment — Confirmed; component-specific gaps stated separately.** Matched placebo contained lactose 78%, corn starch 20%, aerosil 0.5%, talc 1% and magnesium stearate 0.5%. Existing fibromyalgia medication was continued: antidepressants 28/31 (90.3%) versus 26/29 (89.6%), antiepileptics 14/31 versus 12/29. Drug identities, doses/changes and psychotherapy were unreported. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Reported values, changes and between-group/adjusted analyses — Confirmed; component-specific gaps stated separately.** Reported post-minus-baseline changes: B6 -0.67 (SD 2.79), placebo +0.53 (2.18), between-group Mann-Whitney p=.209. Baseline-adjusted endpoint means were 6.73 (95% CI 5.8-7.6) versus 7.64 (6.7-8.5), ANCOVA p=.16, partial eta squared=.034. Arm-mean CIs are not a CI for the difference; adjusted and unadjusted results remain separate. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Design, registered-primary status and multiplicity — Confirmed; component-specific gaps stated separately.** Stratified block randomization, envelope concealment and double blinding are described, but analysis uses 60 completers. Power calculations used pain VAS, not depression. The paper lists multiple primary outcomes including HADS. IRCT20200920048782N2 dated 2021-10-04 is reported in the paper; native registry history and multiplicity correction were not verified. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Clinical importance, response and remission — Not reported/not established; reason stated.** Response/remission, a context-matched MCID and an adjusted contrast CI are unavailable. Derived change difference -1.20 and adjusted-mean difference -0.91 points are different calculations from rounded inputs. Nonsignificance is not equivalence or zero effect. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Funding, product supply and conflicts — Confirmed; component-specific gaps stated separately.** Guilan University of Medical Sciences support and placebo provision by the pharmacology faculty are acknowledged; no competing interests declared. Separate manufacturer financing of B6 was not claimed. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

**Study safety — Confirmed; component-specific gaps stated separately.** No adverse events were reported by participants. Thirty losses, completer analysis and short exposure prevent a claim of established long-term safety in all 90. Losses are not relabeled as 30 adverse events. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7)

### Shiloh et al. 2001 — S05

Uncontrolled augmentation of stable neuroleptic treatment, with route and generalizability limits. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

Source access: `original_abstract_in_authors_institutional_record`; Abstract; Harefuah 2001;140(5):369-373,456.

**Population, diagnosis and severity — Confirmed; component-specific gaps stated separately.** Nine patients with schizophrenia and comorbid minor depression, not interchangeable with MDD. Neuroleptic treatment had been stable for at least four weeks, with less than 5% change in psychosis ratings. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Baseline scale, direction and range — Full text or detailed data inaccessible.** HAM-D was used, but version, score range, baseline raw values and severity are unavailable in the accessed abstract. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**PLP, deficiency and total intake — Full text or detailed data inaccessible.** PLP, deficiency criteria and total B6 intake including diet and co-supplements could not be verified without full text. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Form, salt, active basis, route, dose and duration — Full text or detailed data inaccessible.** The abstract confirms pyridoxine 150 mg/day added for four weeks, but explicit route, salt/active basis, total exposure and PLP could not be verified without full text. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Actual comparator, common care and co-treatment — Confirmed; component-specific gaps stated separately.** Open-label add-on administration without placebo control. Specific neuroleptics, antidepressants/psychotherapy and detailed changes were not verified. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Denominators, completion and attrition — Full text or detailed data inaccessible.** Nine observed patients are reported; separate recruitment/attrition flow denominators are absent from the accessed abstract. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Reported values, changes and between-group/adjusted analyses — Confirmed; component-specific gaps stated separately.** HAM-D use is confirmed but version/range and baseline raw scores are unavailable. Two individuals had reported relative decreases of 23% and 28%. These are not validated response/remission criteria or an established 2/9 treatment-response rate. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Design, registered-primary status and multiplicity — Confirmed; component-specific gaps stated separately.** The design is uncontrolled, open-label augmentation. Registered-primary, multiplicity and missing-data details are inaccessible; no causal monotherapy estimate was calculated. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Clinical importance, response and remission — Full text or detailed data inaccessible.** No validated response/remission definition is added to the individual 23%/28% decreases. Uncontrolled changes are not between-group effects. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Funding, product supply and conflicts — Full text or detailed data inaccessible.** The author-institution abstract lacks funding and product-supply details; funding from other B6 studies is not copied. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

**Study safety — Full text or detailed data inaccessible.** Adverse-event/withdrawal denominators and sensory-neuropathy monitoring are inaccessible; nonreporting is not safety confirmation. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/)

### Khodadad et al. 2021 — S06

Separate pregnancy/postpartum-prevention question, not pooled with general depression treatment or effects in nutrient-sufficient adults. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

Source access: `full_text_html`; Methods; Tables 1-3; Discussion; financial support.

**Population, diagnosis and severity — Confirmed; component-specific gaps stated separately.** Women at 28 weeks of pregnancy at risk of postpartum depression; 86 allocated 43/43, 40/41 completed. Ten suspected MDD cases were excluded/referred; risk screening used HADS, support and stress measures. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Baseline scale, direction and range — Internal source conflict retained.** B6 baseline EPDS conflicts: abstract 10.4 +/-1.4 versus Table 3 10.1 +/-1.4. Placebo baseline is 9.3 +/-4.2; endpoints 4.2 +/-2.7 versus 10.4 +/-3.4. The paper cites an EPDS screening threshold of 13 for Iranian women, not a between-group MCID or remission rate. Paper-specific score range and response/remission analysis remain unverified. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**PLP, deficiency and total intake — Not reported/not established; reason stated.** PLP/blood B6 and deficiency criteria were not established; the study acknowledges limits to diet/activity control. It is not reclassified as proven deficiency correction or supplementation in verified nutrient sufficiency. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Form, salt, active basis, route, dose and duration — Confirmed; component-specific gaps stated separately.** Methods specify two oral 40-mg pills daily (80 mg) from gestational week 28 until birth, followed by 40 mg/day for one month postpartum. The abstract's pregnancy-only summary is not the complete exposure. Assessment was at six weeks postpartum; exact salt/active basis, total intake and PLP were not established. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Actual comparator, common care and co-treatment — Not reported/not established; reason stated.** Similar-looking starch placebo pills were given twice daily during pregnancy and once daily for one month postpartum. Detailed psychiatric co-treatment/dose changes, dietary B6 and activity control were not adequately reported. Development of severe depression/anxiety requiring medication or psychotherapy was an exclusion criterion. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Denominators, completion and attrition — Confirmed; component-specific gaps stated separately.** Eighty-six women were allocated 43/43; 40/41 completed, losses 3/2. Completion denominators are tied to prenatal/postpartum exposure; losses are not assumed to be adverse events. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Reported values, changes and between-group/adjusted analyses — Confirmed; component-specific gaps stated separately.** The reported endpoint EPDS between-group p<.001 is retained but not transferred to general MDD treatment. Single blinding and alternating allocation are described; the RCT title does not establish robust randomization. Native registry history was not verified. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Design, registered-primary status and multiplicity — Confirmed; component-specific gaps stated separately.** Single blinding, alternating allocation and diet/activity control limits are reported. IRCT2016091929873N1 is recorded from the paper, but native registration history/registered-primary status and multiplicity were not verified. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Clinical importance, response and remission — Not reported/not established; reason stated.** The EPDS screening threshold of 13 is not an MCID, response or remission definition. Results concern postpartum prevention in at-risk pregnant women, not standalone treatment in currently depressed general adults. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Funding, product supply and conflicts — Confirmed; component-specific gaps stated separately.** Research support from Isfahan University of Medical Sciences and no conflicts were declared. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

**Study safety — Not reported/not established; reason stated.** No complications were reported, but systematic arm-specific sensory-neuropathy or long-term denominator data are absent. This is not individual dosing advice during pregnancy. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/)

## Arithmetic and clinical interpretation

For Field 2026, the raw placebo-only difference in reduction is (17.8−8.2)−(13.9−10.6)=6.3 DASS points. Using the pooled-control unadjusted F(1,56)=17.02 and B6 n=19/control n=39, the ordinary independent two-group one-way ANOVA relation F=t² and pooled-variance standardized-difference formula give d=sqrt(17.02)×sqrt(1/19+1/39)=1.154210. Direction comes from greater B6 reduction. This is an approximation derived from the rounded original F, not a placebo-only, baseline-adjusted or within-person effect. Pooled-control interpretation and baseline imbalance remain limitations. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) [S11](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2013.00863/full)

For baseline-adjusted F(1,55)=14.00, partial eta squared=14/(14+55)=0.202899 agrees with the reported .20 after rounding; it does not mean 20% improvement. Ordinary ANOVA magnitude benchmarks are not applied to partial eta squared with covariates. Supplied case 28 tier 2 permits statistical magnitude classification when a validated MCID is unavailable. E+ therefore uses Cohen's 0.2/0.5/0.8 convention, not a claim that clinical importance is established. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) [S11](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2013.00863/full)

In fibromyalgia, the reported-change difference is −0.67−0.53=−1.20 HADS-D points, while the difference of adjusted arm means is 6.73−7.64=−0.91. These are different estimands. Arm-mean confidence limits are not subtracted to manufacture a contrast CI, and the original Mann-Whitney p=.209 is not replaced with another test. The OC study's 20%/11% are relative changes, not 20/11 points. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7) [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/)

No cross-study meta-analysis/weighted average, invented CI/MCID/NNT, response/remission rate or active-salt conversion was created. Loss of paired assessments, (325−268)/325=17.54%, and fibromyalgia losses, 30/90=33.33%, describe follow-up/analysis loss, not adverse-event incidence. Original denominator conflicts were not silently reconciled. Inputs, formulas, outputs and assumptions are separated in calculations.json.

## Counterevidence, exclusions and new-study boundaries

**PMS/PMDD.** Reused original source/search maps from 127/3095. Global PMS or cyclical depression items differ from general depressive symptoms; completed verdicts were not regraded.

**B6+B12+folate and cognitive combinations.** Combination depression prevention in 1059, cognitive B-vitamin/VITACOG material in 486 and MCI manuscript 3141 do not establish single-B6 depression efficacy.

**B-complex plus antidepressant.** Kuchya's Neurobion Forte (B1/B2/B3/B6/B12) plus fluoxetine cannot isolate B6. Internal statistical or title/design inconsistencies do not turn it into positive or negative single-B6 evidence. [S14](https://ijmrr.medresearch.in/index.php/ijmrr/article/download/438/847?inline=1)

**Magnesium+B6/multicomponent.** Magnesium+B6, ZMA and other combinations were not pooled as isolated B6 causal effects.

**Older OC/deficiency leads.** Adams 1973 and Winston 1973 were identified bibliographically but full text was blocked. Secondary deficiency/response/dose claims were not promoted to original values. [S12](https://www.sciencedirect.com/science/article/abs/pii/S0140673673913597) [S13](https://psychiatryonline.org/doi/10.1176/ajp.130.11.1217) [S15](https://pubmed.ncbi.nlm.nih.gov/15964874/)

**Diet/PLP association and mechanism.** Dietary/PLP associations, animal work and GABA, cognitive or visual mechanisms are not depression-treatment effects; observational correlations were not converted into randomized oral supplementation effects. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852)

**Ongoing PLP trial.** NCT07469462 studies PLP 100 mg/day for one week versus microcrystalline cellulose, with May-November 2026 recruitment listed. Completed results were not verified in the official summary; it is not registration of the old Field data or proof of P5P equivalence. [S07](https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?distance=&location=&trialId=60218)

## Safety

Caution. Field 2026 reports one B6 withdrawal due to vivid dreams and no reported sensory symptoms, but complete-denominator and long-term safety are unverified. TGA cannot exclude peripheral-neuropathy risk below 50 mg/day and warns about total exposure across B6, magnesium, zinc and other products. The US adult total-intake UL of 100 mg/day and EFSA 2023 UL of 12 mg/day are different frameworks, not prescriptions or safety guarantees. Australian Pharmacist Only scheduling for oral >50-<=200 mg daily preparations is scheduled for 2027-06-01, not already effective or a Korean rule. PLP/P5P is not presumed safer or equally effective, and no individual supplement or antidepressant change is instructed. [S08](https://www.tga.gov.au/news/safety-updates/medicines-containing-vitamin-b6-pyridoxine-pyridoxal-or-pyridoxamine) [S09](https://www.tga.gov.au/news/safety-updates/peripheral-neuropathy-supplementary-vitamin-b6-pyridoxine) [S10](https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/)

The Australian TGA warning for products above 10 mg/day and low-dose/multiple-product reports signal risk; they do not provide dose-specific incidence or an established minimum safe duration. Neuropathy includes tingling, burning or numbness. Nonreporting or no short-term reports do not establish long-term safety in pregnancy, older age, liver/kidney disease or polypharmacy. NIH medication-interaction information is general safety context, not proof of those drugs in trial participants. [S09](https://www.tga.gov.au/news/safety-updates/peripheral-neuropathy-supplementary-vitamin-b6-pyridoxine) [S10](https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/)

## Classification and grading decision

The supplied calculator gives proposed=final C from B/P/R1/I1/E+/B2/CX. One strength (E+) maps to the supplied fixed anchor of 50. E+ is case-28 tier-2 statistical magnitude classification (d approximately 1.154, unadjusted pooled control), not a verified MCID. This score is not treatment success probability, official GRADE or manuscript quality.

| Axis | Value | Reason | |---|---|---| | claim_type | B | Clinical depressive-symptom improvement claim. | | endpoint | P | P reflects actual self-reported depressive symptoms, not a biochemical surrogate S or hard event H. | | replication | R1 | The closest DASS symptom evidence is one exploratory program. R1 is the supplied code's limited single-study mapping, not an assertion of confirmatory status. The 2022/2026 reports overlap; OC and fibromyalgia studies differ in context, so R2 is not awarded. R0 requirements of matched estimands and mutually excluding CIs are not established. | | independence | I1 | University-employment support plus donated Innopure tablets is mixed support, not counted again as a bias flaw. | | effect | E+ | Case 28 tier 2 applies: without a validated clinical criterion, the unadjusted between-group F and n=19/39 yield d approximately 1.154. Cohen 0.2/0.5/0.8 conventions classify magnitude only. E+ does not establish a met MCID or clinical importance. Adjusted partial eta squared is not used as a clinical threshold. | | bias | B2 | Confirmed supplied-list flaws are complete-data selection/substantial attrition and short exposure (30-40 days versus 12 weeks), supporting B2. The symptom subgroup is also small (58), but the whole 325-person recruitment is not mislabeled below 200. Duration limits sustained/relapse inference, not validity of short-term symptom measurement. Baseline imbalance, exploratory multiplicity and outcome-based exclusions add limitations. | | precision | CX | The relevant adjusted between-group point-contrast CI is unreported. Partial eta squared and arm-specific CIs are not converted to a new contrast CI; CX retained. |

Kind S and category mood are retained; R01 is not a new site top-level category. The existing vitamin-b6 token is reused without issuing a permanent code, ID, slug or URL. The calculator's historical E+ label is not treated as proof of a met MCID; the rubric's later case 28 explicitly supports the declared statistical classification.

## Search, verification scope and revision triggers

Limits include the DASS paper's 267/268 and final 254/255 denominator conflicts, exploratory multiplicity, baseline imbalance, complete-data selection, unavailable MCID/adjusted-contrast CI, unverified MDD/PLP/total intake/co-treatment, and inaccessible older or crossover full papers. No exhaustive subscription-database search or individual-data reanalysis was performed.

The search date is 2026-09-17. The 15 entries in search_log.json are exact recorded final/cross-check queries, not an exhaustive export of all preliminary searches or PRISMA counts. Full texts, abstracts, registry summaries and official warnings have distinct access levels in sources.json. Key PDF tables/figures were checked in screenshots, but downloaded original PDF bytes were not preserved and no web-file SHA was invented. Failure to identify a matching correction/retraction notice within this search is not a guarantee that none exists anywhere.

Revision triggers are independent oral single-B6 trials/completed PLP results, verified original/registry denominator or adjusted-contrast CI/nutrition/co-treatment information, and corrections, retractions, numeric/classification errors or new safety warnings. These are conditions for revising a completed current conclusion, not outstanding clinical-decision tasks delegated to another party. Research, numbers, grading, bilingual text, safety and classification decisions are finalized. Pre-submission audit is separate from the initial postpublication corrections=[] history.

result_status=completed_with_uncertainty; content_verification_status=completed_with_declared_scope; editorial_review.status=ready_with_uncertainty; publication_status=needs_id_assignment. first_published_at=null. Only technical identifier/format/conflict/omission/byte checks remain; no clinical revalidation or new-value decision is delegated. No server access, deployment or next task was executed.

## Source map

**S01.** High Dose Vitamin B6 Reduces Depression Symptoms. DOI `10.1155/da/8926512`. PMID `42569537`. [S01](https://onlinelibrary.wiley.com/doi/10.1155/da/8926512) — `full_text_html_and_pdf_screenshots`; Positive exploratory DASS-42 depression subgroup result; not diagnosed MDD, independent replication, or an adjusted placebo-only contrast. Denominator conflicts retained.

**S02.** High-dose Vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression. DOI `10.1002/hup.2852`. PMID `35851507`. [S02](https://onlinelibrary.wiley.com/doi/10.1002/hup.2852) — `full_text_html_and_pdf_screenshots`; MFQ report from the same five-phase program. Depression group-by-time p=.083 was nonsignificant; anxiety and visual results are not substituted.

**S03.** Vitamin B6 Supplementation Reduces Symptoms of Depression in College Women Taking Oral Contraceptives: A Randomized, Double-Blind Crossover Trial. DOI `10.1080/19390211.2022.2030843`. PMID `35109763`. [S03](https://experts.azregents.edu/en/publications/vitamin-b6-supplementation-reduces-symptoms-of-depression-in-coll/) — `original_abstract_in_authors_institutional_record`; Crossover study of eight healthy oral-contraceptive users. BDI-II relative within-period changes are reported; raw scores and paired between-treatment contrast/CI are unavailable without the full paper.

**S04.** Effect of vitamin B6 on pain, disease severity, and psychological profile of fibromyalgia patients; a randomized, double-blinded clinical trial. DOI `10.1186/s12891-022-05637-7`. PMID `35831850`. [S04](https://link.springer.com/article/10.1186/s12891-022-05637-7) — `full_text_html_and_pdf_screenshots`; Add-on B6 trial in women with fibromyalgia, most using antidepressants. Between-group superiority on HADS depression was not established.

**S05.** Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial. PMID `11419053`. [S05](https://cris.tau.ac.il/en/publications/antidepressive-effect-of-pyridoxine-vitamin-bsub6sub-in-neurolept/) — `original_abstract_in_authors_institutional_record`; Uncontrolled add-on observation in nine neuroleptic-treated patients with schizophrenia and minor depression; not B6 monotherapy efficacy.

**S06.** Can Vitamin B6 Help to Prevent Postpartum Depression? A Randomized Controlled Trial. DOI `10.4103/ijpvm.IJPVM_240_19`. PMID `34912512`. [S06](https://pmc.ncbi.nlm.nih.gov/articles/PMC8631136/) — `full_text_html`; Prevention in pregnant women at risk of postpartum depression. MDD exclusion, alternating allocation and an abstract/table baseline EPDS conflict prevent transfer to general depression treatment.

**S07.** The Effects of High-dose Vitamin B6 on Depression and Anxiety Symptoms. [S07](https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?distance=&location=&trialId=60218) — `official_public_trial_summary`; Separate PLP 100 mg, one-week study versus microcrystalline cellulose. No results verified in the public summary; not a preregistration of the older Field data.

**S08.** Medicines containing vitamin B6 (pyridoxine, pyridoxal or pyridoxamine). [S08](https://www.tga.gov.au/news/safety-updates/medicines-containing-vitamin-b6-pyridoxine-pyridoxal-or-pyridoxamine) — `official_safety_update`; Risk cannot be excluded below 50 mg/day; combined-product exposure matters. Pharmacist Only scheduling for oral >50-<=200 mg daily preparations starts on 2027-06-01.

**S09.** Peripheral neuropathy with supplementary vitamin B6 (pyridoxine). [S09](https://www.tga.gov.au/news/safety-updates/peripheral-neuropathy-supplementary-vitamin-b6-pyridoxine) — `official_safety_update`; Peripheral-neuropathy spontaneous reports and >10 mg/day warning scope. No established minimum risk dose or duration; reports do not estimate incidence.

**S10.** Vitamin B6: Fact Sheet for Health Professionals. [S10](https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/) — `official_fact_sheet`; US FNB adult total-intake UL of 100 mg/day and the EFSA 2023 adult UL of 12 mg/day are different frameworks, not depression dose recommendations.

**S11.** Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. DOI `10.3389/fpsyg.2013.00863`. [S11](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2013.00863/full) — `full_text_html`; Methodological basis for deriving d from a two-group change-score ANOVA. Partial eta squared with covariates is not assigned a clinical threshold.

**S12.** Effect of pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraception. DOI `10.1016/S0140-6736(73)91359-7`. [S12](https://www.sciencedirect.com/science/article/abs/pii/S0140673673913597) — `publisher_bibliographic_search_record; full_text_inaccessible`; Original publisher search records establish the 1973 paper and DOI. Secondary claims about deficiency counts, dose and response were not promoted to verified original values.

**S13.** Oral contraceptives, pyridoxine, and depression. DOI `10.1176/ajp.130.11.1217`. PMID `4795720`. [S13](https://psychiatryonline.org/doi/10.1176/ajp.130.11.1217) — `bibliographic_record_only; full_text_inaccessible`; A separate 1973 oral-contraception paper was located bibliographically, but original clinical values were inaccessible; missing data are not negative effects.

**S14.** Role of vitamin B supplementation with Fluoxetine in treatment of depression: A randomized controlled clinical trial. DOI `10.17511/ijmrr.2016.i01.014`. [S14](https://ijmrr.medresearch.in/index.php/ijmrr/article/download/438/847?inline=1) — `full_text_html`; Neurobion Forte B1/B2/B3/B6/B12 plus fluoxetine versus fluoxetine cannot isolate B6. Combination effects and internally inconsistent statistics are not used for single-B6 efficacy.

**S15.** The role for vitamin B-6 as treatment for depression: a systematic review. DOI `10.1093/fampra/cmi040`. PMID `15964874`. [S15](https://pubmed.ncbi.nlm.nih.gov/15964874/) — `original_abstract_and_publisher_preview; full_review_inaccessible`; Used only to map older literature; article counts are not equivalent trial counts and review numbers are not original-trial verification.

Why this is classified as C (50)

The supplied calculator gives proposed=final C from B/P/R1/I1/E+/B2/CX. One strength (E+) maps to the supplied fixed anchor of 50. E+ is case-28 tier-2 statistical magnitude classification (d approximately 1.154, unadjusted pooled control), not a verified MCID. This score is not treatment success probability, official GRADE or manuscript quality.

Counterpoint. Limits include the DASS paper's 267/268 and final 254/255 denominator conflicts, exploratory multiplicity, baseline imbalance, complete-data selection, unavailable MCID/adjusted-contrast CI, unverified MDD/PLP/total intake/co-treatment, and inaccessible older or crossover full papers. No exhaustive subscription-database search or individual-data reanalysis was performed.

Rejudgment record. Evidence relies substantially on an exploratory subgroup in a short single program. Field 2022 and 2026 are not independent replications; OC, fibromyalgia and postpartum-prevention evidence has different directness boundaries. — The supplied calculator gives proposed=final C from B/P/R1/I1/E+/B2/CX. One strength (E+) maps to the supplied fixed anchor of 50. E+ is case-28 tier-2 statistical magnitude classification (d approximately 1.154, unadjusted pooled control), not a verified MCID. This score is not treatment success probability, official GRADE or manuscript quality.

Review performed and remaining limitations

Limits include the DASS paper's 267/268 and final 254/255 denominator conflicts, exploratory multiplicity, baseline imbalance, complete-data selection, unavailable MCID/adjusted-contrast CI, unverified MDD/PLP/total intake/co-treatment, and inaccessible older or crossover full papers. No exhaustive subscription-database search or individual-data reanalysis was performed.

Search scope and limitations. Web searches on 2026-09-17 covered Korean/English names, molecular forms, MDD/symptoms, negative results, registration and correction leads, followed by primary-source access; see search_log.json.

Evidence Table

Receipt — 15 References

Evidence access cutoff: 2026-09-17. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.